Welcome to our dedicated page for FINDIT news (Ticker: FDIT), a resource for investors and traders seeking the latest updates and insights on FINDIT stock.
Findit, Inc. (Ticker: FDIT) is a dynamic company that owns and operates the social media content management platform known as Findit.com. This innovative platform functions as an interactive search engine, enabling users to post, share, and manage their content. Once content is posted on Findit, it becomes accessible to major search engines such as Google, Yahoo, and Bing for indexing. This ensures that content appears in Findit search results and can also be organically indexed by outside search engines, thereby increasing visibility and reach.
In a significant strategic move, Findit, Inc. announced on January 12, 2024, the submission of its 14C Information Statement. This pivotal document provided comprehensive details on an impending merger with BioRegenx, Inc., a company specializing in regenerative biotherapeutics and anti-aging research. The merger aims to integrate BioRegenx's advanced medical and wellness technologies with Findit's robust content management capabilities.
BioRegenx, Inc. operates as a holding company with a focus on acquiring cutting-edge intellectual property and innovative companies. It aims to develop non-invasive medical devices capable of efficiently collecting, storing, and analyzing extensive health datasets. These datasets are used to generate predictive outcomes through proprietary algorithms and advanced AI engines. BioRegenx's core mission is to equip healthcare practitioners, patients, and consumers with actionable insights derived from in-depth data analysis, thereby enhancing the precision and effectiveness of health solutions.
The merger will see the integration of BioRegenx's subsidiaries, which include Microvascular Health Solutions, LLC; MyBodyRx, LLC; NuLife Sciences, Inc.; Regenr8, Inc.; and DocSun Biomedical Holdings, Inc. These subsidiaries focus on various aspects of health and wellness, from microvascular health to anti-aging supplements and non-contact vital signs monitoring systems.
Findit, Inc. is committed to developing monetized internet-based web products that enhance brand awareness for its members. These products include options for URL submissions for indexing in Findit search results and the ability to post status updates that can be crawled by external search engines. This comprehensive approach ensures that all posts on Findit can be shared across other social and bookmarking sites by both members and non-members.
BioRegenx, Inc. has announced a new peer-reviewed study published in Pediatric Critical Care Medicine, focusing on glycocalyx biomarkers in children with sepsis. The study, conducted by Jaime Fernández-Sarmiento and colleagues, utilized the GlycoCheck™ system to assess the impact of unbalanced and balanced crystalloids on the endothelial glycocalyx. Findings revealed that unbalanced fluids lead to glycocalyx degradation, heightening risks of vascular permeability and kidney failure. The GlycoCheck system, FDA registered, has been featured in over 100 studies and is crucial for monitoring microvascular health. Ongoing studies are further evaluating their Endocalyx Pro™ supplement.
BioRegenx, Inc. and Findit, Inc. have announced a merger agreement as BioRegenx reveals a new peer-reviewed study on
Endocalyx Pro™ in the International Journal of Molecular Sciences. The research indicates that Endocalyx Pro
restores and protects the endothelial glycocalyx in kidney patients exposed to toxic hemodialysis plasma. Damage to
this glycocalyx is linked to increased cardiovascular risks among Chronic Kidney Disease patients. The study indicates
Endocalyx Pro can prevent glycocalyx damage and shows effective results in mouse models. The product is patented and
distributed by Microvascular Health Solutions.
Findit, Inc. (OTC PINK:FDIT) has announced a merger with BioRegenx, Inc., approved by both boards, expected to close in Q1 2023, pending regulatory approval. This deal results in BioRegenx controlling 90% of Findit’s voting securities, with significant stock exchanges occurring. A reverse stock split of 1 for 25 is planned to attract institutional investors. BioRegenx, focusing on regenerative healthcare, aims to enhance Findit's marketing and product offerings, leveraging its subsidiaries and patented technologies.
Findit, Inc. (OTC PINK:FDIT) has updated its Investor Relations page to assist investors in transferring paper certificates to Book-Entry shares, following their recent switch to Clear Trust as their Transfer Agent. Secretary Tom Powers invites inquiries directly and emphasizes ongoing efforts in company growth, including technology enhancements and new client acquisition, alongside the preparation of quarterly reports and a forthcoming Shareholder update. Findit.com, the company's social media platform, enables enhanced brand visibility through content management and indexing in major search engines.
Findit, Inc. (OTC PINK:FDIT) announced a new partnership with Rentalz.com, a vacation rental marketplace under Resortia Group. Rentalz differentiates itself by collaborating solely with professional property managers and not charging guest booking fees, allowing guests to save an average of 10% compared to major competitors like Airbnb and VRBO. The platform boasts around 50,000 listings nationwide and aims for rapid expansion. Findit will aid in enhancing Rentalz's web presence through SEO and content services, targeting improved traffic without incurring high Pay-Per-Click costs.
FAQ
What is the current stock price of FINDIT (FDIT)?
What is the market cap of FINDIT (FDIT)?
What is Findit, Inc.?
What is the significance of the 14C Information Statement submitted by Findit, Inc.?
Who is BioRegenx, Inc.?
What are the primary products and services offered by Findit, Inc.?
What are the recent achievements of Findit, Inc.?
How does BioRegenx, Inc. enhance healthcare solutions?
What subsidiaries are included in BioRegenx, Inc.?
What is the GlycoCheck device?
What is Endocalyx Pro?
What impact does the merger have on Findit, Inc.?
